Objective: The aim of the study was to compare the effects of vitamin D 3 supplementation versus placebo on serum sex hormones in postmenopausal women completing a 12-month diet þ exercise weight loss program.
O besity is an established risk factor for postmenopausal breast cancer, [1] [2] [3] although the underlying mechanisms have not been fully elucidated. Elevated sex hormone concentrations are hypothesized to play a role as adipose tissue is the primary peripheral site of aromatase production, and therefore, the primary site of sex steroid hormone synthesis after menopause. [4] [5] [6] [7] Vitamin D insufficiency is frequently observed with obesity 8, 9 ; low vitamin D status is also associated with postmenopausal breast cancer risk. A meta-analysis of nine prospective studies examining circulating vitamin D showed a nonlinear inverse association between vitamin D and breast cancer risk, with diminishing benefit above 35 ng/mL 10 in postmenopausal, but not premenopausal, women. In addition, in vitro and in vivo studies show that calcitriol, the hormonally active form of vitamin D, decreases aromatase expression and attenuates estrogen signaling in breast cancer cells. 11 Other proposed mechanisms through which vitamin D status may affect breast cancer risk include effects on cell division, apoptosis, and contact inhibition. 12 The purpose of this study was to investigate the effects of 12 months of vitamin D 3 supplementation (2,000 IU/d) versus placebo on changes in sex steroid hormones, including estradiol, estrone, testosterone, and sex hormone-binding globulin (SHBG) among overweight and obese postmenopausal women with low circulating vitamin D (serum 25-hydroxyvitamin D 25[OH]D !10 to <32 ng/mL), participating in a lifestyle-based weight loss program. We hypothesized that given excess sex hormones levels in overweight and obese postmenopausal women, vitamin D in conjunction with weight loss would provide additional sex hormone-lowering effects compared with weight loss alone.
METHODS
This study is ancillary to the Vitamin D, Diet, and Activity (ViDA) study (www.clinicaltrials.gov Identifier NCT01240213)-a 12-month, double-blind, placebo-controlled randomized trial comparing the effects of 2,000 IU/day oral vitamin D 3 (cholecalciferol) supplementation versus placebo on weight and biomarkers of breast cancer risk, in postmenopausal women participating in a weight loss program. 13 Study procedures were reviewed and approved by the Fred Hutchinson Cancer Research Center Institutional Review Board. All participants provided written informed consent.
Study participants
The study is described elsewhere. 13 Briefly, 218 postmenopausal (50-75 y) women with a body mass index (BMI) at least 25 kg/m 2 and serum 25(OH)D concentrations at least 10 ng/mL and less than 32 ng/mL (''insufficient'') were randomly assigned to 12 months of either 2,000 IU/day vitamin D 3 supplementation þ a lifestyle-based weight loss program (n ¼ 109; ''Vitamin D''); or daily placebo þ a lifestyle-based weight-loss program (n ¼ 109; ''Placebo''). Exclusion criteria included: taking above 400 IU supplemental vitamin D; renal disease; history of kidney stones; diagnosed diabetes, osteoporosis, or severe congestive heart failure; history of breast cancer or other invasive cancer excluding nonmelanoma skin cancer; hormone therapy use within the past 6 months; alcohol intake more than 2 drinks/day; current smoking; contraindication to taking 2,000 IU vitamin D 3 /day; history of bariatric surgery; use of weight loss medications; additional factors that might interfere with the measurement of outcomes or intervention success (eg, inability to attend facility-based sessions).
Women were recruited primarily through mass-mailings and media publicity. Invitation letters (n ¼ 6,253) were mailed to potentially eligible women identified from a database of previous study participants and women who had expressed an interest in our studies. In total, 2,147 women returned an interest survey, 498 of whom met the initial eligibility criteria and were invited for vitamin D screening. Of these, 310 were eligible based on study 25(OH)D criteria (!10.0 ng/mL and <32.0 ng/mL). A total of 264 women underwent a clinic screening interview and 218 women were randomized into the study (Fig. 1) . 13 
Randomization and interventions
Participants were randomized by permuted blocks randomization (1:1), stratified according to BMI (<30 or !30 kg/m 2 ) and whether consent was given for optional breast and abdominal fat biopsies. All staff except statisticians were blinded to the randomization status. The number of women randomized to each arm did not differ by season (P > 0.99).
The vitamin D and matching placebo (sunflower oil) gel capsules were created and bottled in unmarked containers by J.R. Carlson Laboratories, Inc (Arlington, IL). At randomization, participants received a 6-month supply of study medications. Medication bottles were returned at 6 months and remaining capsules were counted before a second 6-month supply was provided. Likewise, at 12 months, the second bottle and any remaining capsules were returned and counted. Ten percent of the study medication bottles were randomly chosen for quality assurance at 6 and 12 months. Moreover, 100% of the tested capsules matched the assigned content provided by the laboratory. Medication counts and the 12-month change in serum vitamin D were used as indicators of study medication adherence.
The ViDA weight loss program, administered to all participants, included both a diet and exercise component adapted from a successful intervention originally based on the Diabetes Prevention Program and Look Ahead weight loss programs. 14, 15 and previously used by our group in a similar study population. [14] [15] [16] The goals of the program were total daily energy intake of 1,200 to 2,000 kcal/day based on baseline weight, less than 30% daily energy intake from fat, at least 45 minutes of moderate-to-vigorous intensity exercise 5 days/week, and a 10% reduction in body weight. Exercise sessions were performed in our supervised facility and at home. 13 Diets were not supplemented with calcium, but women were advised on how to obtain sufficient calcium in their diets.
Women receiving vitamin D 3 attended a mean 56.1% of all diet-counseling sessions and completed a mean (standard deviation [SD]) 138 (147) min/wk of moderate-to-vigorous physical activity, whereas women in the placebo arm attended a mean 59.5% of diet sessions and completed a mean (SD) 147 (140) min/wk of activity. The 12-month change in vitamin D intake from dietary sources and supplements did not differ between study arms (P ¼ 0.60). Both groups increased their average pedometer steps per day (þ2,602 and þ2,816 steps/d, respectively) compared to baseline. No significant differences in adherence to the weight loss program were detected between study arms.
Outcome measures
Before randomization and at 12 months, participants provided a 50-mL blood sample after fasting for 12 hours, not exercising for 24 hours, or drinking alcohol for 48 hours. Blood was processed within 1 hour and serum stored at À708C until analysis.
Vitamin D was measured at Heartland Assays, Inc (Ames, IA) with a direct, competitive chemiluminescence immunoassay (CLIA) using the DiaSorin LIAISON 25-OH Vitamin D Total assay, which is cospecific for 25(OH)D 3 and 25(OH)D 2 . The inter and intra-assay coefficients of variation (CVs) for this assay were 11.2% and 8.1%, respectively.
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All other laboratory assays were performed at the Reproductive Endocrine Research Laboratory (University of Southern California, Los Angeles, CA). Estrone, estradiol, and total testosterone were quantified by specific radioimmunoassays after organic solvent extraction and Celite column partition chromatography. 17, 18 SHBG was measured with a chemiluminescent immunoassay using the Immulite analyzer (Siemens Medical Solutions Diagnostics, Malvern, PA) to allow calculation of bioavailable (free þ albuminbound) estradiol and testosterone. 19 Baseline and 12-month samples from each individual were included in the same batch, and participants' samples were randomly placed across batches. Serum 25(OH)D was measured as previously described. 13 Interassay CVs ranged from 5% to 18% for the sex steroid hormone assays; the interassay CV for the SHBG assay was 6%.
Covariates
Demographic information, medical history, anthropometric measures, and lifestyle behaviors, including sun exposure, physical activity, dietary intake, and supplement use, were collected as previously described. 13 
Safety and adverse events
All participants were interviewed after 1, 3, 6, 9, and 12 months of study participation for any signs or symptoms of vitamin D toxicity or other adverse events, including serious illness or hospitalizations. Reports were reviewed by a physician's assistant with appropriate follow-up as necessary. Summary data were recorded and reviewed according to the study group by an independent Data and Safety Monitoring Committee at 6-month intervals.
Statistical analyses
Assuming 80% power in this sample, we calculated minimal detectable absolute differences between study arms of 8% to 14% for our outcomes.
Age-adjusted partial correlation coefficients were calculated between baseline measures. Outcome measures were log-transformed to improve distribution normality and are presented as geometric means AE 95% confidence interval (CI) unless otherwise noted. Mean 12-month changes between groups were compared using the generalized estimating equation (GEE) modification of linear regression to account for intraindividual correlation over time. Models
Not randomized N=46
Did not meet eligibility criteria =34
Declined participation =12 were initially unadjusted, and subsequently adjusted for age, race/ethnicity (white, other), baseline 25(OH)D, baseline BMI, total vitamin D intake (diet þ nonstudy supplements), average sun exposure (h/d), and total 12-month weight loss.
The GEE approach for mixed-model regression using available data was applied to address missing data. Additional analyses were based on post-hoc analyses of specific subgroups. Outcomes were compared across tertiles ; lost <5% baseline weight; lost !5% to <10% baseline weight; lost !10% baseline weight. 16 All statistical tests were two-sided. Statistical analyses were performed using SAS software (version 9.3, SAS Institute Inc, Cary, NC).
RESULTS
The baseline characteristics of randomized women are shown in Table 1 . 13 The majority (86%) were non-Hispanic white. The mean age and BMI were 59.6 AE 5.1 years and 32.4 AE 5.8 kg/m 2 , respectively. The mean baseline serum 25(OH)D concentration was 21.4 AE 5.1 ng/mL. At 12 months, 187 (86%) women provided a blood sample; however, only 55% remembered to return their unused study pills. Thus, complete pill counts are available only for a subset of 
VITAMIN D, WEIGHT LOSS, AND SEX HORMONES
participants (Vitamin D: 54%; Placebo: 56%), but compliance was high among them (Vitamin D: 98%; Placebo: 96%). Six women were excluded from analyses because of serum estradiol values outside of acceptable postmenopausal ranges (>42 pg/mL). 20 Serum 25(OH)D increased a mean of 13.6 ng/mL in the vitamin D arm and decreased a mean of 1.3 ng/mL in the placebo arm over 12 months (P < 0.0001). The mean weight change was À8.2% in the vitamin D arm compared with À8.4% in the placebo arm (P ¼ 0.41). 13 At baseline, serum 25(OH)D was positively associated with total vitamin D intake (r ¼ 0.20, P ¼ 0.02), but not with serum estrone (r ¼ À0.07, P ¼ 0.33), total, free, or bioavailable estradiol (all r ¼ À0.1, P > 0.05), or SHBG (r ¼ 0.004, P ¼ 0.95). Serum 25(OH)D was significantly inversely associated with total, free, and bioavailable testosterone (all r ¼ À0.15, P ¼ 0.03).
Although sex hormone concentrations were reduced in both groups, the mean magnitude of change over 12 months was not significantly different between the vitamin D and placebo arms for any outcome measure (all P > 0.05; Table 2 ). However, when stratified according to magnitude of change in 25(OH)D using tertiles, greater increases in serum 25(OH)D were associated with greater increases in SHBG in a dose-dependent manner (P trend ¼ 0.01), and with greater decreases in free and bioavailable estradiol (P trend ¼ 0.04, P trend ¼ 0.03, respectively) after adjusting for age, race/ethnicity, baseline BMI, baseline serum 25(OH)D, vitamin D intake (diet þ nonstudy supplements), average sun exposure, and total 12-month weight loss (Table 3) .
Compared with women randomized to the vitamin D arm who did not become replete despite supplementation (n ¼ 38), women who became replete (ie, 25[OH]D !32 ng/mL; n ¼ 53) by 12 months showed a greater reduction in free estradiol (À0.07 vs À0.03 pg/mL; P ¼ 0.03) and bioavailable estradiol (À1.
and bioavailable testosterone (À1.8 vs À0.6 ng/dL; P ¼ 0.003), and a greater increase in SHBG (10.6 vs 4.7 nmol/L; P ¼ 0.005), after adjusting for age, race/ethnicity, baseline BMI, baseline 25(OH)D, total vitamin D intake, and average sun exposure. Further adjustment for total 12-month weight loss attenuated these associations, but most remained statistically significant (Table 4) .
In analyses limited to women with complete study pill counts, SHBG increased to a larger degree in the vitamin D arm compared with the placebo arm (Vitamin D 
DISCUSSION
Over two-thirds of American women are overweight or obese, 21 and approximately 75% have vitamin D levels below 30 ng/mL, which is generally considered insufficient. 22 Although our results suggest no overall benefit of 2,000 IU/day vitamin D supplementation on reducing sex hormone concentrations beyond the effect of weight loss alone in postmenopausal women, a greater increase in 25(OH)D was significantly associated with decreases in free and bioavailable estradiol, and increases in SHBG. Moreover, repletion to levels at least 32 ng/mL was associated with significantly greater rises in SHBG and significant reductions in bioavailable estradiol, and free and bioavailable 
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testosterone, compared with women whose circulating 25(OH)D remained below 32 ng/mL; these effects were independent of total weight loss.
In analyses limited to women with complete pill counts, among whom medication adherence was 97% and changes in 25(OH)D were þ15.7 ng/mL and À1.1 ng/mL in the vitamin D and placebo arms, respectively, estradiol decreased, and SHBG increased significantly more in the vitamin D arm compared with that in the placebo arm. Although a significant mean increase in serum 25(OH)D was still observed in the vitamin D arm compared with the placebo arm (10.1 vs À1.8 ng/mL; P < 0.001) among women without complete pill counts, lower compliance in a subset of study participants may have diminished the overall strength of the observed outcomes.
Weight loss through caloric restriction and exercise has been shown to significantly reduce biomarkers of postmenopausal breast cancer risk 20 ; however, to our knowledge, no other studies have examined the effects of vitamin D supplementation on sex steroid hormones during weight loss. It remains unknown whether vitamin D-related outcomes are more strongly related to a specific magnitude of change in 25(OH)D (eg, 10 ng/mL) or to a change in status defined by reaching a specific threshold level (eg, >32 ng/mL). This remains an important area for future investigation, as does the effect of individualizing vitamin D therapy to repletion at specific levels.
Strengths of our study include its double-blind, randomized controlled design and its relatively long duration. However, all significant results were based on post-hoc analyses of subgroups; thus, our results should be considered hypothesis-generating for future studies. There remains no consensus definition for vitamin deficiency and insufficiency, 23 ,24 and we may have observed stronger effects using a more stringent definition of insufficiency in our study sample. For example, we excluded women with serum 25(OH)D concentrations below 10 ng/mL, among whom the effect of vitamin D supplementation could be more pronounced. Additionally, we tested only one dose of supplementation, had complete study medication counts for only 55% of participants, and did not test the independent effects of vitamin D without a weight loss intervention. Finally, because our study population was relatively homogeneous, our results may not be generalizable to other racial/ ethnic groups.
CONCLUSIONS
The relationships between vitamin D and sex steroid hormones warrant further investigation in carefully designed studies to more fully elucidate its potential role in the prevention of postmenopausal breast cancer. 
